Huntington Bancshares is under mounting pressure from all sides — the stock is sliding, analysts are trimming targets for the third consecutive week, and the October earnings date is now less than a month away.
The analyst story has become a steady drip of target reductions without any rating changes. Since last week's note flagged Wells Fargo's Mike Mayo cutting from $23 to $21, two more firms have followed. Evercore ISI trimmed to $18 on September 18, and Truist Securities lowered to $19 on September 23 — both maintaining positive ratings but acknowledging the stock has fallen further than their prior models assumed. DA Davidson also cut from $22 to $20 earlier in the week. Every firm keeps its constructive rating intact, but the consensus price target has drifted down to $19.83 against a stock now trading at $15.69. That's a gap of roughly 26% to the mean target — wide enough to look interesting on paper, yet the direction of travel on targets makes it hard to anchor to. The bull case centres on acquisitions in Texas and the Southeast driving fee revenue diversification. The bear case is more immediate: net interest income pressure, credit costs, and competition in legacy markets.
The price action reinforces the concern. HBAN fell 2.2% on Tuesday and is down 6.3% on the week, extending a one-month decline to nearly 8%. The weakness is not company-specific — regional banks as a group have had a rough week. Close peers and dropped 5.6% and 6.8% respectively, while fell 3.5% and lost 5.3%. HBAN's decline is near the middle of this peer cluster, suggesting sector-wide pressure rather than a stock-specific catalyst.
Short positioning tells a more measured story than the price move implies. Short interest is 3.4% of the free float — elevated from a month ago, when it sat closer to 2.9%, but still a moderate level by most standards. The intra-week spike to around 71 million shares on September 17 unwound almost entirely by September 22, dropping back to 53.4 million shares. That reversal looks more like a transient positioning event than a sustained short buildup. Borrow conditions are extremely relaxed: cost to borrow has eased to 0.39%, down roughly 25% on the week, and availability is running near 8,400% — meaning there are almost two billion shares available to borrow against roughly 53 million shorted. The lending market is placing no squeeze pressure on HBAN at all. The ORTEX short score of 32 sits in the lower half of the universe, consistent with a mildly shorted stock with loose borrow conditions.
Options traders are not particularly defensive either. The put/call ratio of 0.877 is actually a touch below its 20-day average of 0.887, putting it near neutral on a z-score basis. At the 52-week low of 0.30, options positioning has been far more hedged at other points this year. Right now the options market is not pricing unusual fear around the October 22 earnings date, which is the next genuine catalyst on the calendar. That said, HBAN's last two quarterly prints produced negative reactions — a 5% one-day drop after July results and a roughly 2.5% decline after the April print. Back-to-back negative post-earnings moves tend to make the market cautious into the next report, even when options positioning doesn't yet reflect it.
Institutional holders are largely passive at these levels. BlackRock has trimmed its position from 10.1% to 8.1% per the most recent 13G/A filing from April, a meaningful reduction. T. Rowe Price and State Street both sit just below the 5% threshold in their most recent disclosures. None of the large holders carry activist intent — all filings on record are passive 13G submissions. The key variable heading into October 22 is whether the net interest income trajectory looks any better than the Q2 miss that prompted Bank of America's downgrade to Neutral in late July; that is the data point the trimming analysts are all waiting on.
See the live data behind this article on ORTEX.
Open HBAN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
